News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 49–60 of 243 stories

T-Therapeutics Raises $133m Series B for TCR Bispecific Programmes

T-Therapeutics has raised $133m in an oversubscribed Series B round led by Advent Life Sciences and British Business Bank, with Johnson & Johnson Innovation, Lilly, Samsara BioCapital and M Ventures joining as new investors. The Cambridge company will use the funds to take two TCR-CD3 bispecific programmes, one in oncology and one in autoimmune disease, into the clinic.

AbbVie Expands Oxford R&D Site as Part of Wider UK Investment

AbbVie has expanded its research and development presence in Oxford with a new 12,000-square-foot site supporting immunology, neuroscience and oncology. The facility builds on capabilities acquired with Oxford-based DJS Antibodies in 2022. It forms part of a broader UK research investment exceeding £120 million; the company has not said that the full amount was spent on the Oxford building alone.

bit.bio Secures $25m Series D to Expand Human Cell Portfolio

Cambridge-based bit.bio has secured $25 million (approximately £19 million) in Series D funding, with backing reported from M&G Investments and Abcam founder Jonathan Milner. The company plans to expand its portfolio of human iPSC-derived cell models and improve access for researchers. It reported a 76% increase in paid vial volumes during 2026, alongside growth in orders and active customers.

Shield Therapeutics Drops 2026 Operating Profit Target in Q3 Update

Shield Therapeutics no longer expects operating profitability in 2026 and now guides to a single-digit million US dollar operating loss, citing the cost of taking full US commercial control of ACCRUFeR on 1 October. US ACCRUFeR net revenue rose 5% to $10.8 million in the third quarter, group revenue was $11.5 million and cash was $6.8 million at 30 September.

Evestia Clinical Acquires Belgian Medical Writing Firm Emtex Life Science

Evestia Clinical, an independent contract research organisation, has acquired Emtex Life Science, a Belgian specialist in regulatory medical writing with more than 25 years of experience. Terms were not disclosed. Emtex will keep its services and teams, with chief executive Mario De Witte and head of QA Mieke Notenbaert continuing to run the business.

Milner Researcher Wins Quantum Funding for Drug Target Discovery

Dr Namshik Han, Head of AI and Computational Research at the Milner Therapeutics Institute, has received a research funding award through the University of Cambridge’s IonQ Quantum Innovation Centre. His group plans to apply quantum computing methods to drug-target discovery and aims to select and test a candidate target in human cells by 2029. The institute did not disclose an award amount.

OGT Adds Four IVDR-Certified CytoCell FISH Probes for Blood Cancers

OGT has expanded its CytoCell portfolio with four fluorescence in situ hybridisation (FISH) probes newly certified under the EU In Vitro Diagnostic Regulation (IVDR). The assays, including ATM and IGH-targeting probes, were already available under the older IVDD framework and support cytogenetic assessment of haematological malignancies. Their certification forms part of OGT's staged transition ahead of the December 2028 Class C deadline.

Allergy Therapeutics Proposes AIM Delisting and Private Status

Allergy Therapeutics has proposed cancelling admission of its shares to AIM and re-registering as a private limited company, citing low share liquidity, valuation concerns and listing costs. The proposal requires approval from at least 75% of votes cast at its annual general meeting. Its two major shareholders have indicated support, while the company says it will continue to explore a possible Hong Kong listing.

MitoRx Therapeutics Appoints Neil Anderson as Chief Business Officer

MitoRx Therapeutics has appointed Neil Anderson as Chief Business Officer, effective 3 November 2026, as the company advances its preclinical obesity candidate MTRX31 towards clinical development. Anderson joins from Novo Nordisk, where he held investment and business development responsibilities, and previously served as Global Head of Business Development at Evaxion Biotech. He will report to co-founder and Chief Executive Officer Jon Rees.

Synexa Life Sciences Appoints COO and CSO in Leadership Changes

Synexa Life Sciences has appointed Jordyn van Teylingen as Chief Operating Officer and Natalie Strickland as Chief Scientific Officer. Van Teylingen, previously Co-Chief Scientific Officer, will oversee operational delivery, digital initiatives and internal systems, while Strickland takes sole responsibility for scientific leadership. The company provides biomarker and bioanalytical services for pharmaceutical, biotechnology and CRO clients.

Sareum Reports Narrower Annual Loss and SDC-1801 Progress

Sareum reported a pre-tax loss of £3.5 million for the year ended 30 June 2026, compared with £4.9 million a year earlier, with no revenue. In its accompanying development update, the company confirmed completion of dosing in the Phase 2-enabling toxicology programme for SDC-1801 in July. Full toxicology results are expected during the fourth quarter of 2026, with further formulation and regulatory work ongoing.